Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells
出版年份 2018 全文链接
标题
Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells
作者
关键词
-
出版物
Frontiers in Immunology
Volume 9, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2018-04-19
DOI
10.3389/fimmu.2018.00814
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Trastuzumab emtansine: determining its role in management of HER2+ breast cancer
- (2018) Deborah B Doroshow et al. Future Oncology
- Influence of physical activity on the immune system in breast cancer patients during chemotherapy
- (2018) Thorsten Schmidt et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Recent advances of bispecific antibodies in solid tumors
- (2017) Shengnan Yu et al. Journal of Hematology & Oncology
- HER2-positive breast cancer
- (2017) Sibylle Loibl et al. LANCET
- Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
- (2017) Véronique Diéras et al. LANCET ONCOLOGY
- Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
- (2017) Ian E Krop et al. LANCET ONCOLOGY
- The making of bispecific antibodies
- (2017) Ulrich Brinkmann et al. mAbs
- Next generation antibody drugs: pursuit of the 'high-hanging fruit'
- (2017) Paul J. Carter et al. NATURE REVIEWS DRUG DISCOVERY
- CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells
- (2017) M. Peipp et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors
- (2017) Takahiro Ishiguro et al. Science Translational Medicine
- Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy
- (2017) Christian Kellner et al. TRANSFUSION MEDICINE AND HEMOTHERAPY
- The Ambiguous Role of γδ T Lymphocytes in Antitumor Immunity
- (2017) Guranda Chitadze et al. TRENDS IN IMMUNOLOGY
- Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
- (2017) Aura Muntasell et al. Frontiers in Immunology
- Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial
- (2016) Jifang Gong et al. BMC CANCER
- HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer
- (2016) Kathy Miller et al. BMC CANCER
- PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
- (2016) Angel Guerrero-Zotano et al. CANCER AND METASTASIS REVIEWS
- Immunotherapy for breast cancer: past, present, and future
- (2016) Alison Spellman et al. CANCER AND METASTASIS REVIEWS
- Tumor microenvironment: The culprit for ovarian cancer metastasis?
- (2016) Zhongyue Luo et al. CANCER LETTERS
- Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer
- (2016) Mark Abramovitz et al. Clinical Breast Cancer
- Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients
- (2016) Hans-Heinrich Oberg et al. PANCREATOLOGY
- Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer
- (2016) Debora de Melo Gagliato et al. Oncotarget
- Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention
- (2016) Nadia F. Nocera et al. Frontiers in Pharmacology
- Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ERpos/HER2pos early breast cancer
- (2016) Lea Lowenfeld et al. OncoImmunology
- Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer
- (2016) Jashodeep Datta et al. JAMA Oncology
- γδ T cell activation by bispecific antibodies
- (2015) Hans-Heinrich Oberg et al. CELLULAR IMMUNOLOGY
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Progressive loss of anti-HER2 CD4+T-helper type 1 response in breast tumorigenesis and the potential for immune restoration
- (2015) Jashodeep Datta et al. OncoImmunology
- Neutrophils with protumor potential could efficiently suppress tumor growth after cytokine priming and in presence of normal NK cells
- (2015) Rui Sun et al. Oncotarget
- HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development
- (2014) J C Singh et al. BRITISH JOURNAL OF CANCER
- Novel Bispecific Antibodies Increase T-Cell Cytotoxicity against Pancreatic Cancer Cells
- (2014) H.-H. Oberg et al. CANCER RESEARCH
- Anti-HER2 Cancer Therapy and Cardiotoxicity
- (2014) Tania Babar et al. CURRENT PHARMACEUTICAL DESIGN
- Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
- (2014) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Successful adoptive transfer and in vivo expansion of haploidentical γδ T cells
- (2014) Martin Wilhelm et al. Journal of Translational Medicine
- Quality of Life in the Trastuzumab for Gastric Cancer Trial
- (2014) Taroh Satoh et al. ONCOLOGIST
- HER2 therapies and gastric cancer: A step forward
- (2014) Ramon Andrade de Mello WORLD JOURNAL OF GASTROENTEROLOGY
- Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy
- (2014) Hans-Heinrich Oberg et al. Frontiers in Immunology
- NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
- (2013) R. Romee et al. BLOOD
- Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC
- (2013) Chandan Verma et al. Journal of Translational Medicine
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies
- (2013) Diana P. English et al. Molecular Diagnosis & Therapy
- T-helper-1-cell cytokines drive cancer into senescence
- (2013) Heidi Braumüller et al. NATURE
- Natural Killer Cell Mediated Antibody-Dependent Cellular Cytotoxicity in Tumor Immunotherapy with Therapeutic Antibodies
- (2013) Ursula J. E. Seidel et al. Frontiers in Immunology
- Pertuzumab: new hope for patients with HER2-positive breast cancer
- (2012) M. Capelan et al. ANNALS OF ONCOLOGY
- Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
- (2012) J Harder et al. BRITISH JOURNAL OF CANCER
- Human T Lymphocytes Are Licensed for Professional Antigen Presentation by Interaction with Opsonized Target Cells
- (2012) N. Himoudi et al. JOURNAL OF IMMUNOLOGY
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- (2012) José Baselga et al. LANCET
- The novel tribody [(CD20)2xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells
- (2012) P Glorius et al. LEUKEMIA
- Lipocalin2 Promotes Invasion, Tumorigenicity and Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma
- (2012) Lisa Leung et al. PLoS One
- Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM x Anti-CD3)
- (2011) M. Jager et al. CANCER RESEARCH
- HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
- (2011) Devika Gajria et al. Expert Review of Anticancer Therapy
- Stimulated T Cells Increase the In Vivo Efficacy of Trastuzumab in HER-2+ Breast Cancer
- (2011) A.-H. Capietto et al. JOURNAL OF IMMUNOLOGY
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes
- (2010) Mothaffar F. Rimawi et al. CANCER
- Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma
- (2010) Christian Röder et al. EUROPEAN JOURNAL OF CELL BIOLOGY
- Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant
- (2009) David M. Gershenson et al. GYNECOLOGIC ONCOLOGY
- Human T Cells: A Lymphoid Lineage Cell Capable of Professional Phagocytosis
- (2009) Y. Wu et al. JOURNAL OF IMMUNOLOGY
- Cross-presenting human T cells induce robust CD8+ T cell responses
- (2009) M. Brandes et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Vγ9Vδ2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs—Rituximab and trastuzumab
- (2008) Hirotake Tokuyama et al. INTERNATIONAL JOURNAL OF CANCER
- Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu
- (2008) Alessandro D. Santin et al. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now